SEC EDGARSEP 161 min read$VCYT

Holstein Jens sold $205K of VCYT

Holstein Jens sold 5,000 shares of VERACYTE, INC. (VCYT) at $40.95 ($0.20M total) on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Holstein Jens

Published Sep 16, 2026, 8:08 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 16, 2026, 8:16 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$VCYT

Bearish

medium confidence

Mentioned

$VCYT

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$VCYTBearishLow

Why it matters

A modest director sale may prompt short‑term selling pressure but is unlikely to drive significant price movement.

Market read

Primary relevance is to Veracyte shareholders; broader market impact is minimal.

What to watch

Potential upcoming clinical data releases or partnership news could offset the negative perception.

Relevance 3/10Novelty 4/10Timing: same‑day filing

Background

Form 4 filing discloses insider transactions; directors often use 10b5‑1 plans for scheduled sales.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$VCYTBearishMedium confidence

Context

Director Jens Holstein sold 5,000 Veracyte shares for $204,747 on 2026-09-14 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

The sale size is small relative to float, but director involvement adds weight; no other catalyst present.

Market effects

Sector

Limited impact on the genomics/diagnostics sector; similar insider sales have minimal sector ripple.

Regional

US market only; no broader regional effect.

Global

Low global relevance; confined to Veracyte investors.

Counterpoint

What could challenge this read

The sale could be routine liquidity planning under a 10b5‑1, not a bearish signal.

Key entities

Company
Veracyte, Inc.
NASDAQ‑listed genomics diagnostics firm.
Insider
Jens Holstein
Director of Veracyte executing a pre‑arranged sale.

Read at source ← All news

OCT 23

$VCYTMedAI 8/10

Veracyte, Inc. (VCYT) Decipher Test Shown to Predict Abiraterone Benefit in Very High-Risk Prostate Cancer

Veracyte reported that its Decipher Prostate test can predict which very high-risk nonmetastatic prostate cancer patients may benefit from adding abiraterone to ADT, based on a retrospective Phase III STAMPEDE analysis. The test's evidence base now extends to predicting treatment benefit, not just risk stratification.

tradingview.com2 min

OCT 23

$VCYTMedAI 8/10

An 11% five-year benefit against prostate cancer spread came with added treatment for men with very high test scores.

Veracyte (VCYT) announced new data showing its Decipher Prostate Genomic Classifier can predict benefit from adding abiraterone to ADT in high-risk prostate cancer patients. The analysis, presented at ESMO 2026, showed 11% 5-year benefit in reducing metastasis for high-risk patients. The findings support broader adoption of Decipher in treatment decisions.

stocktitan.net2 min

OCT 16

$VCYTMed

Veracyte, Inc. (VCYT) Wins Medicare Coverage for Prosigna Test

Veracyte (VCYT) announced Medicare coverage for its Prosigna Breast Cancer test, effective August 19, 2026, for eligible patients. The decision marks an early commercialization milestone, according to the company.

tradingview.com1 min

OCT 16

$VCYTMed

A breast cancer test could spare chemotherapy for more than two-thirds of clinically high-risk patients

Veracyte's Prosigna test for early-stage breast cancer received Medicare coverage, enabling reimbursement for eligible patients. The test helps determine chemotherapy necessity, sparing over two-thirds of high-risk patients, per the OPTIMA trial. Veracyte (VCYT) aims for broader adoption and access.

stocktitan.net2 min

SEP 14

$VCYTHigh

VERACYTE, INC. (VCYT): Completion of Acquisition or Disposition of Assets

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the

SEC EDGAR 8-K2 min

JUL 30